STAFF BOARD
Article
CHAIRMAN
Virginia Hernández Corredoira
EDITOR IN CHIEF
Manuela Velázquez Prieto
Jaime E. Poquet Jornet
MARKETING MANAGER
EDITORIAL BOARD
Ramón Jódar Masanés
Lluís Campins Bernadas
Tomás Casasín Edo
Juan Carlos Juárez Giménez
Carles Quiñones Ribas
Volume 22 - Issue 1, January-March 2020
SPECIAL ARTICLES
DUPILUMAB FOR TREATING MODERATE TO SEVERE ATOPIC DERMATITIS
SÁNCHEZ RUIZ ANDRÉS, CANTUDO CUENCA MARÍA DOLORES


Dupilumab is the first monoclonal antibody developed for treating atopic dermatitis (AD) and is indicated in moderate to severe AD in adult patients who are candidates for systemic therapy. Three pivotal trials (CHRONOS, SOLO-1 and SOLO-2) evaluated response with dupilumab versus placebo in patients with an inadequate response to topical therapy, using as co-primary endpoints at least a 75% reduction in the EASI score from when treatment started (EASI 75) and a rating of "clear" (score of 0) or "almost clear" (score of 1) on the IGA and at least a 2-point improvement from baseline. Results confirmed the efficacy of dupilumab, but the clinical relevance is not clear. The trials also demonstrated improvements in some other secondary
efficacy endpoints, such as quality of life or other patient-reported outcomes.
Treatment-related adverse events, when we detected relevant differences, were: eye disorders, injection site reaction and conjunctivitis. Therefore, dupilumab is an appropriate option in adult patients who do not respond adequately to topical therapies or for whom topical therapy is inadvisable and that also had not achieved satisfactory response to cyclosporine.

ATOPIC DERMATITIS – ATOPIC ECZEMA – DUPILUMAB – EFFICACY – SAFETY



Fill out the form below to buy this article

Name and surname:

DNI/NIF ID/VAT IDENTIFICATION No.:

Contact Email:

Phone:

Address:

Zip code:

City:

Province:

Country:

*I have read and accept the privacy policy
Price : 30,25